ViaCyte, Inc.

Award Value
Disease Team Research I: Allan Robins Cell Therapy for Diabetes $22,999,933
Early Translational I: Olivia Kelly Methods for detection and elimination of residual human embryonic stem cells in a differentiated cell product $5,405,397
Tools and Technologies I: Evert Kroon Development of the Theracyte Cellular Encapsulation System for Delivery of human ES Cell-derived Pancreatic Islets and Progenitors. $827,072
Strategic Partnership I: Howard Foyt Preclinical and clinical testing of a stem cell-based combination product for insulin-dependent diabetes $10,075,070
Disease Team Planning: Emmanuel Baetge Development of a Cell Replacement Therapy Product for Insulin Dependent Diabetes $48,950
Total:
$39,356,422.00
Icon for xls export